The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
EMA extends the license indications for rituximab and venetoclax
The therapeutic potential of two lymphoma therapies has been broadened following the January 2019 European Medicines Agency (EMA) meeting. The EMA has announced license extensions of rituximab and the combination of venetoclax with obinutuzumab.1
The anti-CD20 monoclonal antibody, rituximab, has now been licensed for the treatment of children (≥ six months old) with advanced diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma.1
The EMA has also extended the use of venetoclax in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL).1 The combination was approved for this indication by the U.S. Food and Drug Administration (FDA) on May 15, 20192 — read more on the Lymphoma Hub here. The National Institute for Health and Care Excellence (NICE) is currently deciding if the treatment regimen should become available on the NHS.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content